Furthermore, some trials have demonstrated structured diabetes control programs achieving targeted glycemic control by using daily blood glucose monitoring results as a basis to self-adjust insulin dose in poorly or uncontrolled type 2 diabetes patients [28]. This evidence concerns the gene INS and diabetes mellitus.